A direct inhibitory effect of cyclosporin A on the growth of a human leukaemia cell line was reported by Foa et al. in 1981 in . Totterman et al. (1982 looked further at its effect on malignant T lymphocytes in vitro, finding that cyclosporin A was selectively cytotoxic and cytostatic to the abnormal cells of the Sezary syndrome. A case is reported in which conventional treatment of the Sezary syndrome had failed to control the unpleasant symptoms of the disease. Therapy with cyclosporin A was instituted, producing excellent symptomatic relief.
Case report
A 58-year-old man presented with a gradually progressive, highly irritating rash, thinning of the hair and dystrophy of the nails.
The erythema of face and chest had started 5j years earlier, when biopsy had been consistent with a diagnosis of early cutaneous T-cell lymphoma. Since diagnosis he had had treatment with strontium beta-ray therapy to a dose of 2000 rad over the whole body, eight individual radiotherapy sessions to the skin, topical nitrogen mustard therapy, and topical steroid therapy.
On presentation to our department in 1981, there was a bright erythematous and slightly infiltrated rash over the face, neck, scalp, trunk and proximal limbs, with patchy hyperpigmentation over the chest. Lymph nodes were enlarged in the axillae, groin, epitrochlear regions and anterior chest wall. The node in the right axilla was 10 cm in diameter. The liver was palpable 6 cm below the right costal margin.
Urea, electrolytes and liver function tests, proteins and immunoglobulins were normal. The haemoglobin level was 16 g/dl, but the white count was raised to 17.5 x 109/l, of which 67% were lymphocytes, some having the characteristic cerebriform nuclei of the Sezary syndrome. There was no abnormality on sternal marrow examination, and chest X-ray showed no 'Case presented to Section of Dermatology, 21 October 1982. Accepted 27 April 1983 0141-0768/83/121063-03/$0l .00 mediastinal lymphadenopathy. In the skin biopsy, lymphocytes, some with little cytoplasm and large irregular nuclei, were packed densely in the upper dermis, 'and in places formed collections in the epidermis. A similar infiltration was seen expanding the paracortical T-cell area of the lymph node biopsy, and within the liver biopsy. Accordingly, a diagnosis of Sezary syndrome of late stage and poor prognosis was made (Epstein et al. 1.972).
PUVA treatment increased his discomfort, despite the additional use of antihistamines and emollients, and during the course the absolute lymphocyte count rose to 32000, of which 50% of the T cells were OKT8-negative. Prednisolone 40 mg daily was introduced, first in combination with cyclophosphamide and later with continuous low-dose chlorambucil (Winkelmann & Linman 1973) . Seven leukopheresis sessions resulted in a drop in the lymphocyte count, but relief of itching and erythema was only short-lived (Pineda & Winkelmann 1981) .
At this stage, although the blood count had fallen and the liver and lymph nodes were no longer palpable, the itching was of intolerable severity. We therefore considered using cyclosporin A. Lymphocyte viability studies were done in vitro, by culturing for 72 hours after separation from the blood, with a range of concentrations'of cyclosporin A. Viability was assessed by dye exclusion. At concentrations of 1 pg/ml and higher, reduction in lymphocyte viability was clearly seen over the 72 hours (Table 1) .
In August 1982 the patient was started on cyclosporin A in a dose of 17.5 mg/kg/day, and within a week there was dramatic clearing of the oedema and erythema, with relief of the itching.
He was no longer taking sleeping pills. The dose of oral prednisolone was successfully lowered from 25 mg to 1O mg over six weeks, whereas previous such attempts had always met with increased' itching. The blood counts remained static, with lymphocyte counts remaining between 7.0 and 12.0 x 109/1. Repeated lymphocyte marker studies six weeks later showed 15% OKT8-negative cells.
There was a rapid rise in liver function tests within nine days of starting cyclosporin A at the dose of 900 mg twice daily: aspartate transaminase 180 U/ml (normal 5-35), gamma glutamyl transpeptidase 240 U/ml (normal 5-45), bilirubin 80 pmol/ml (normal 1-25). These levels fell quickly to within normal limits when cyclosporin A was stopped, and subsequently remained normal on smaller doses.
Renal function presented a greater problem, with urea rising rapidly to 13 mmol/l (normal 2.5-7) and creatinine to 150 pmol/l (normal 50-125). Although these improved with reduction in dose of cyclosporin A, after six weeks of therapy the dose had to be limited to between 500 and 600 mg daily in order to keep the urea between 10 and 14 mmol/l and creatinine between 130 and 160 pmol/l. The creatinine clearance was reduced to 85 ml/min after two months, urinary protein remaining less than 0.1 g/l over 24 hours.
A repeat skin biopsy showed less epidermotropism, although a heavy collection of abnormal lymphocytes remained in the upper dermis.
In order to keep the urea to between 10 and 20 mmol/l, the dose of cyclosporin A is currently maintained at 300 mg twice daily; the serum level measured on one occasion at two hours after the dose was 250 ng/ml. Excellent symptomatic relief has been maintained with this dose, although itching returns within 24 hours if the drug is stopped. The patient has reported nausea which may be due to the cyclosporin A.
Discussion
Cyclosporin A, introduced by Borel and coworkers in 1976, is a cyclic polypeptide of low molecular weight isolated from soil fungi. It is rapidly absorbed from the gut, peaking at 2-7 hours and falling progressively over 12 hours.
In man, cyclosporin A has been used to prolong the survival of renal (Calne et al. 1979) , bone marrow (Powles et al. 1978 ) and liver (Morris 1981) allografts. Pretreatment before transplantation does not influence graft survival, suggesting that it only inhibits lymphocytes which have been exposed to a stimulating antigen. In this respect, it prevents the early activation of T lymphocytes by antibody-assisted interleukin I (Palacios & Moller 1981) , and also inhibits production of interleukin II which is needed to support the further growth of the colony.
The side effects so far seen include nephrotoxicity, hepatotoxicity, tremor, hirsutism, and gingival hyperplasia (Ringden et al. 1982). All these changes are reversible on reducing the dose or stopping the drug.
The nature of the renal toxicity is uncertain, but is thought to be a tubular effect. Renal scans have always shown normal blood flow and reduced clearance (Klintmalm et al. 1981) . A study reporting the histology of kidneys in rats given large doses of the drug showed no ultrastructural damage (Thompson et al. 1981) .
There is difficulty in establishing the exact risk of lymphoma developing in patients treated with cyclosporin A, as most patients have had other immunosuppression in addition. An incidence of between 5 and 6% has been quoted for neoplasia developing in transplant patients receiving conventional immunosuppression (Homan 1981), while Calne et al. (1979) reported 3 cases of lymphoma in renal transplant patients on cyclosporin A. In a series of pooled results totalling 1300 transplant patients, there were 13 cases of lymphoma, although only one had been treated with cyclosporin A alone (Beveridge 1983).
Our patient seems very sensitive to the toxic effects of cyclosporin A and was able to tolerate only about half the dose commonly used after renal transplantation. It is also disappointing that there has not been any objective evidence of clearance of Sezary cells from the blood or dermis. The relief of symptoms in this case has been so dramatic that it suggests a genuine effect of cyclosporin A, perhaps reducing the attraction of the S6zary cells to the epidermal environment.
Addendum: Cyclosporin A was withdrawn after ten months therapy when a renal biopsy showed patchy tubular atrophy and quite extensive interstitial fibrosis. Control of the itching again became a major problem. The patient died two months later and post-mortem was refused. Kartagener's syndrome is a triad of situs inversus, chronic sinusitis and bronchiectasis. Only a fifth of all cases of situs inversus have bronchiectasis and other features ofthis syndrome (Adams & Churchill 1937 , Olsen 1943 . It has recently been shown that patients with Kartagener's syndrome share a defect of ciliary motility and therefore reduced lung mucociliary clearance, immotile sperm tails and various abnormalities of ciliary ultrastructure (Afzelius 1979) . A patient with situs inversus alone is described in whom these matters were investigated.
Situs inversus and ciliary immotility'

Case report
A 41-year-old Punjabi woman was referred for investigation ofpalpitations. She was noted to have complete situs inversus, first discovered in her second pregnancy. Her palpitations were found to be benign in origin, and she agreed to be investigated for ciliary function. She had no history of sinusitis, postnasal drip, chronic cough or recurrent chest infection, nor was there anything to suggest atopy or asthma. She had one or two colds per year, and had never smoked. She had had vitiligo since the age of16 and had had two full term, normal deliveries. Her Physical examination showed only a sinus tachycardia 'and vitiligo (but no signs of thyrotoxicosis) and complete situs inversus, with dextrocardia and gastric air bubble producing resonance at the right costal margin and liver dullness on the left. X-rays of frontal sinuses were normal. A chest X-ray showed dextrocardia but normal lung fields, and oral cholecystogram confirmed situs inversus. Thyroid function tests, full blood count and differential, protein strip, immunoglobulins and alpha1 anti-trypsin levels were all normal. Rheumatoid factor and autoantibodies were not present. Pulmonary function tests (Table 1) were consistent with small airways disease. There was no reversibility with salbutamol.
Ciliary beat frequency (CBF) was measured on brushings from the inferior turbinate of the left nostril. This was examined under a binocular microscope and CBF (Table 2 ) measured photometrically (Pedersen & Mygind 1980). Mucociliary clearance was measured by inhaling an aerosol of' 5 pm-diameter polystyrene particles tagged with 99UTc. Clearance was then measured with two scintillation detectors over a six-hour period, so that whole lung clearance was observed. If the activity remaining at 24 hours is taken as alveolar deposition, then subtracting this from the above measurements leaves a rate of decline due to tracheobronchial clearance (TBC) (Thomson 
